Zepbound Price Changes: Every Dated Move From December 2025 to Now

What Zepbound costs changed five times between December 2025 and July 2026, and most pages still quote a price from one of the earlier windows. This is the dated ledger: what changed, on what date, with the primary document for each — so you can tell whether the figure you are looking at is current or eleven months stale.

The short version. The self-pay vial ladder you see today — $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 mg up — has been in place since December 1, 2025¹. Everything after that date changed who can get a lower price or in what device, not the ladder itself. If a page quotes $349–$499, it is citing the pre-December 2025 prices. If it says the ladder took effect in February 2026, it has attached the right numbers to the wrong event — February 23 is the KwikPen's date, not the vials'³.

December 1, 2025 — the vial price cut that set today's ladder

Lilly lowered the self-pay price of Zepbound single-dose vials on LillyDirect, its own direct-to-consumer pharmacy. Three tiers moved at once¹²:

• •2.5 mg: $349 → $299 a month (a $50 reduction)
• •5 mg: $499 → $399 a month (a $100 reduction)
• •7.5, 10, 12.5 and 15 mg: $499 → $449 a month

This is the single most consequential date on the page, because it is the ladder still in force today. It is also the source of most stale pricing on the web: $499 was the old 5 mg and high-dose figure, and it is still widely republished as if it were current — including, on some pages, as the lapsed-refill price, which it is not.

The prices carry a condition that has not changed since: they hold inside the Zepbound Self Pay Journey Program, which requires each refill within about 45 days of your previous delivery. Miss that window and the dose reverts to Lilly's regular price — $599 at 7.5 mg, $699 at 10 mg, $849 at 12.5 mg, $1,049 at 15 mg¹. We work through what that costs over a year in Zepbound vials vs pens.

February 5, 2026 — TrumpRx.gov launches

The federal price-comparison portal TrumpRx.gov went live, listing drugs from the first five manufacturers to reach most-favored-nation pricing agreements — AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer⁴.

For Zepbound specifically, this changed the price by nothing. TrumpRx is a directory, not a pharmacy: its Zepbound listing routes the order to LillyDirect, at the LillyDirect price. The portal's headline discount is calculated against the $1,087 list price, which is how it arrives at "up to 72% off" — a real saving if you were paying retail, and no saving at all if you were already buying self-pay. We take that listing apart in TrumpRx and Zepbound.

February 23, 2026 — the four-dose KwikPen

The FDA approved a label expansion allowing Zepbound to be delivered through a four-dose, single-patient-use KwikPen — a full month of once-weekly injections in one device, with no syringe to draw from a vial. Lilly made it available through LillyDirect the same day, and priced it on the same self-pay ladder as the vials, starting at $299 for the 2.5 mg tier³.

So February 23 changed the format, not the price. That distinction matters more than it sounds: this is the date most commonly misreported as the day the $299/$399/$449 prices took effect, when those had already been in force for nearly three months. It also matters for Medicare, because the Bridge below covers the KwikPen and only the KwikPen — a device that did not exist until this date.

May 1, 2026 — the FDA's 503B bulk-substances notice

The FDA published a Federal Register notice on the list of bulk drug substances for which there is a clinical need under section 503B — the mechanism that governs what outsourcing facilities may compound⁵.

This is the one entry that is not about brand pricing at all, and it belongs here because it shapes the compounded market that most of this site's readers are actually shopping in. Compounded tirzepatide is priced by telehealth programs rather than by Lilly, and its legal footing narrowed once the national shortage resolved. The status and what it means for a program you are considering is in is compounded tirzepatide still legal?.

July 1, 2026 — the Medicare GLP-1 Bridge

The largest price change of the five, for the people it covers. Under a CMS demonstration running July 1, 2026 through December 31, 2027, eligible Medicare Part D enrollees can fill the Zepbound KwikPen for a flat $50 monthly copay⁶.

The limits are as important as the number:

• •KwikPen only. Zepbound single-dose vials and single-dose pens are excluded — which is why the February 23 date above is load-bearing.
• •Part D enrollees, 18 or older, prescribed for weight management and meeting the BMI criteria.
• •The $50 does not count toward your Part D deductible or the $2,100 out-of-pocket cap, and cannot be spread through the Medicare Prescription Payment Plan.
• •Not a route for type 2 diabetes, sleep apnea or MASH prescriptions, which go through ordinary Part D.

Before July 2026, the answer for weight management alone was a flat statutory no, and that exclusion still governs everything outside the demonstration. Full eligibility rules are in does Medicare cover tirzepatide.

What did not change

Three figures have held throughout, and they are worth knowing because they anchor every comparison on this site:

• •The auto-injector pen list price: about $1,087 a month, flat across doses. This is the "before" number in nearly every discount claim you will read.
• •The commercial savings card: as little as $25 a month if your plan covers Zepbound, up to 13 fills a year.
• •The non-covered savings card: $499 a month for the single-dose pen. This figure is a frequent source of confusion: $499 is a savings-card price, not the lapsed-refill price, and not the old vial price either, though it happens to match the latter.

How to tell whether a price you are reading is current

Three quick tests, in order of how often they catch something:

1. 1.Does it say $349 or quote $499 as the vial price? Then it predates December 1, 2025.
2. 2.Does it state a refill condition? The $449 tier is conditional on a roughly 45-day refill window. A page that quotes $449 without the condition is quoting the best case as the price.
3. 3.Does it carry a date at all? Ours do, and so does every row on our provider price index, which recomputes on each build. A cash price with no verification date is the single best predictor that it is wrong.

For the full picture of what you would actually pay by route, see Zepbound cost and savings; for the compounded market's own pricing, the cheapest tirzepatide programs.

The bottom line

The Zepbound self-pay ladder — $299 / $399 / $449 by dose, on a 45-day refill condition — has been unchanged since December 1, 2025¹. What moved after that was access, not the ladder: TrumpRx (February 5) added a federal front door to the same LillyDirect price⁴; the four-dose KwikPen (February 23) added a format at the same price³; the FDA's 503B notice (May 1) shaped the compounded market rather than the brand one⁵; and the Medicare GLP-1 Bridge (July 1) put the KwikPen at $50 a month for eligible Part D enrollees through the end of 2027⁶. If a page quotes $349–$499, or dates the current ladder to February 2026, it is working from a superseded window.